MINNEAPOLIS and DUNDEE, Scotland, July 28,
2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH) today announced the signing of an exclusive licensing
agreement to commercialize The University of
Dundee's BromoTAG® system and fund the recruitment of
postdoctoral researchers at the University's Centre for Targeted
Protein Degradation (CeTPD). CeTPD researchers will create new
chemical tools that will be commercialized by Tocris, a Bio-Techne
brand, for use by the biopharmaceutical research
community.
BromoTAG enables scientists to determine which individual
proteins possess the greatest potential as a target for new
therapeutic agents. Using genome-editing technologies, BromoTAG
pins a small biological tag to a target protein and labels it for
subsequent modifications, for example cellular degradation,
allowing researchers to evaluate its functional role and impact on
disease development. BromoTAG was developed by Conner Craigon and Adam
Bond, PhD students at CeTPD and is a powerful chemical
biology tool, enabling the rapid and selective removal of any
individual protein. It has been shown to degrade the tagged protein
at low concentration, within minutes, and reversibly. Critically,
it degrades only the individual target protein and prevents any
off-target effects.
The University of Dundee is a leader
in Targeted Protein Degradation (TPD), a field of research that is
revolutionising drug discovery. This approach is making the
treatment of diseases previously thought to be undruggable a
reality. Dundee researchers and
teams led by CeTPD Director, Professor Alessio Ciulli, have previously revealed
fundamental insights into the working of the degrader molecules
that they have designed and that are used across the globe.
Professor Ciulli is a pioneer in protein degraders research, while
Tocris has strong know-how and expertise in organic chemistry. Over
the past five years, Tocris has been working with Professor Ciulli
to commercialize various chemical tools such as inhibitors and
degraders developed in his lab.
"We are excited about TPD, both as an enabling technology for
life science research, as well as for its potential to deliver new
therapeutics in the clinic," said Will
Geist, Bio-Techne's Protein Sciences Segment President.
"Bio-Techne has built a leading portfolio of tools and technologies
to support scientists through every stage of their TPD research,
and we are delighted to offer BromoTAG to researchers through this
exclusive license. We have a long-standing relationship with the
University of Dundee to commercialize
exciting and useful technologies and look forward to expanding this
relationship through our support of post-doctoral research."
Professor Ciulli said, "We are delighted to announce the
successful commercialization of a recent CeTPD discovery, and for
continued collaborative work between Dundee and Tocris. We will jointly work to
develop the next-generation BromoTAG for a variety of applications.
The licensing deal deepens the relationship between the University
and Bio-Techne. These developments cement the importance of our
research to the field of targeted protein degradation."
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-441
BromoTag® is a registered trademark of the
University of Dundee
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-licensing-agreement-and-partnership-with-university-of-dundee-301594422.html
SOURCE Bio-Techne Corporation